339.80
price up icon2.80%   9.25
after-market After Hours: 345.00 5.20 +1.53%
loading
Alnylam Pharmaceuticals Inc stock is traded at $339.80, with a volume of 2.05M. It is up +2.80% in the last 24 hours and up +4.20% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$330.55
Open:
$335
24h Volume:
2.05M
Relative Volume:
2.18
Market Cap:
$44.31B
Revenue:
$2.35B
Net Income/Loss:
$-269.70M
P/E Ratio:
-162.58
EPS:
-2.09
Net Cash Flow:
$-75.39M
1W Performance:
+4.35%
1M Performance:
+4.20%
6M Performance:
+22.60%
1Y Performance:
+45.33%
1-Day Range:
Value
$333.03
$345.98
1-Week Range:
Value
$323.74
$345.98
52-Week Range:
Value
$205.87
$345.98

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Name
Alnylam Pharmaceuticals Inc
Name
Phone
(617) 551-8200
Name
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Employee
2,230
Name
Twitter
@alnylam
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ALNY's Discussions on Twitter

Compare ALNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 43.10B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 120.29B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.26B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 33.09B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-21-25 Initiated Truist Buy
Mar-31-25 Initiated Redburn Atlantic Buy
Mar-24-25 Upgrade JP Morgan Neutral → Overweight
Nov-12-24 Downgrade Wolfe Research Peer Perform → Underperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Aug-16-24 Upgrade Goldman Neutral → Buy
Feb-16-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-08-23 Initiated Wells Fargo Equal Weight
Oct-11-23 Downgrade Oppenheimer Outperform → Perform
Sep-29-23 Initiated Raymond James Outperform
May-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-26-23 Initiated SMBC Nikko Neutral
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Buy
Sep-09-22 Resumed Morgan Stanley Equal-Weight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-27-22 Downgrade Guggenheim Buy → Neutral
Jun-07-22 Initiated William Blair Outperform
Apr-25-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-01-22 Initiated Citigroup Buy
Feb-03-22 Upgrade Guggenheim Neutral → Buy
Jan-03-22 Upgrade Piper Sandler Neutral → Overweight
Nov-22-21 Upgrade Goldman Neutral → Buy
Nov-22-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-01-21 Upgrade Oppenheimer Perform → Outperform
Oct-04-21 Upgrade UBS Neutral → Buy
Aug-04-21 Downgrade Piper Sandler Overweight → Neutral
Feb-22-21 Downgrade Guggenheim Buy → Neutral
Feb-12-21 Downgrade Citigroup Buy → Neutral
Feb-12-21 Reiterated H.C. Wainwright Buy
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-30-20 Resumed Berenberg Hold
Sep-08-20 Initiated Citigroup Buy
Aug-11-20 Downgrade Oppenheimer Outperform → Perform
May-13-20 Initiated RBC Capital Mkts Sector Perform
May-07-20 Downgrade JP Morgan Overweight → Neutral
Apr-24-20 Resumed Evercore ISI Outperform
Mar-19-20 Initiated Berenberg Buy
Dec-19-19 Reiterated Chardan Capital Markets Buy
Nov-20-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
May-23-19 Resumed Goldman Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Mar-06-19 Upgrade Evercore ISI In-line → Outperform
Mar-05-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19 Initiated UBS Neutral
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-13-18 Reiterated Stifel Buy
Aug-07-18 Upgrade Stifel Hold → Buy
May-04-18 Reiterated Stifel Hold
Mar-28-18 Initiated Evercore ISI In-line
View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

pulisher
03:39 AM

From inception to launch: City Therapeutics finds space in the heart of innovation - JLL

03:39 AM
pulisher
09:41 AM

Alnylam Pharmaceuticals stock hits all-time high at 335.0 USD By Investing.com - Investing.com Nigeria

09:41 AM
pulisher
09:34 AM

Bernstein raises Alnylam Pharmaceuticals stock price target on Amvuttra outlook - Investing.com Canada

09:34 AM
pulisher
Jul 29, 2025

Raymond James assumes coverage on Alnylam stock with Outperform rating - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 22:59:43 - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Market Forecast Review For 2025 - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-29 02:19:48 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-29 01:41:26 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthOutstanding capital returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are Alnylam Pharmaceuticals Inc. company’s key revenue driversStay informed with daily expert analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Risk adjusted return profile for Alnylam Pharmaceuticals Inc. analyzedChart Breakout Buy Signal Detection Confirmed - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What makes Alnylam Pharmaceuticals Inc. stock price move sharplyMaximize gains with proven stock analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

How does Alnylam Pharmaceuticals Inc. compare to its industry peersDiscover undervalued stocks before they soar - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Alnylam Pharmaceuticals Inc.Navigate market volatility with smart strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Alnylam Pharmaceuticals Inc. in the next 12 monthsUncover the best stocks for explosive growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attentionFree Join Group - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyInvest smarter with data-backed trading alerts - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Alnylam Pharmaceuticals Inc. stock priceDynamic investment growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Alnylam Pharmaceuticals Inc. stockSuperior profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Tessera cuts jobs amid financial challenges - statnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

Huntington's Disease Clinical, Companies, Therapeutic - openPR.com

Jul 23, 2025
pulisher
Jul 22, 2025

Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Alnylam Pharmaceuticals Surges to Top 277 Most Actively Traded Stocks with $412 Million in Trading Volume Following FDA Approval of Patisiran - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Is Alnylam Pharmaceuticals Inc. a good long term investmentHigh-profit capital plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - 富途牛牛

Jul 22, 2025
pulisher
Jul 22, 2025

Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

10 Most Undervalued Healthcare Stocks to Buy According to Analysts - Insider Monkey

Jul 21, 2025
pulisher
Jul 21, 2025

Lexicography: Clear And Unequivocal - The National Law Review

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $390,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Truist Securities initiates Alnylam Pharmaceuticals stock with Buy rating By Investing.com - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jul 21, 2025
pulisher
Jul 19, 2025

Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment and Market Impact - The Globe and Mail

Jul 19, 2025

Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$598.89
price up icon 0.02%
biotechnology ONC
$299.94
price down icon 1.90%
$554.58
price down icon 0.64%
$110.05
price down icon 1.28%
$26.66
price down icon 0.30%
Cap:     |  Volume (24h):